Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?
| Autor: | Chantal Mathieu, Robert Colebunders, Rodrigo Moreno-Reyes, Evelyne van Etten, Lut Lynen, Anali Conesa-Botella, Luc Kestens |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
Calcitriol Inflammation urologic and male genital diseases Virologie générale Calcitriol receptor vitamin D deficiency Immune reconstitution inflammatory syndrome Virology medicine Vitamin D and neurology Macrophage Pharmacology (medical) cardiovascular diseases Adverse effect business.industry urogenital system fungi Virologie médicale Biologie moléculaire Hypothesis medicine.disease female genital diseases and pregnancy complications Immunology Molecular Medicine Human medicine medicine.symptom lcsh:RC581-607 business medicine.drug |
| Zdroj: | AIDS Research and Therapy, 6 AIDS Research and Therapy AIDS Research and Therapy, Vol 6, Iss 1, p 4 (2009) Aids research and therapy |
| ISSN: | 1742-6405 |
| Popis: | Background: About 20-30% of persons with HIV infection, especially those living in countries with limited resources, experience an immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral treatment. The active form of vitamin D, 1,25-dihydroxyvitamin D, is a key player in the clearance of pathogens and influences the level of inflammation and macrophage activation. Presentation of the hypothesis: We hypothesize that low availability of 1,25-dihydroxyvitamin D, either due to vitamin D deficiency or due to polymorphisms in the vitamin D receptor or in its activating/ inactivating enzymes, contributes to the appearance of IRIS. Furthermore, drug interactions with the enzymatic pathways of vitamin D could favour the development of IRIS. Testing the hypothesis: Our hypothesis could be explored by a case-control study to assess the prevalence of vitamin D deficiency in HIV-infected patients on antiretroviral treatment who develop and do not develop IRIS. Implications of the hypothesis: If the role of vitamin D in IRIS is confirmed, we would be able to screen patients at risk for IRIS by screening for vitamin D deficiency. After confirmation by means of a clinical trial, vitamin D supplementation could be a cheap and safe way to reduce the incidence of IRIS. © 2009 Conesa-Botella et al; licensee BioMed Central Ltd. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink